New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:43 EDTENZY, ACST, NEPTNeptune, Acasti say patent settlement with Enzymotec not finalized
Neptune Technologies (NEPT) and Acasti Pharma (ACST), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec (ENZY) that would resolve the International Trade Commission investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. the Administrative Law Judge presiding over the pending ITC Investigation previously stay the proceedings through February 5 to give the parties more time to finalize a settlement agreement. To date, the parties have reached an impasse on certain fundamental settlement terms, including terms to which Enzymotec had already agreed in the parties' signed term sheet. Consequently, as strongly encouraged by the ITC, Neptune will participate in the ITC's Mediation Program in a final attempt to reach a mutually satisfactory agreement. The mediation process is expected to be completed over the next 45 to 60 days.
News For NEPT;ACST;ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:08 EDTNEPTNeptune Technologies appoints Jim Hamilton as CEO
Subscribe for More Information
November 13, 2014
07:39 EDTENZYEnzymotec sees FY14 EPS 36c-45c, consensus 36c
Sees FY14 revenue $47M-$50M, consensus $48.5M.
07:37 EDTENZYEnzymotec reports Q3 EPS 5c, consensus 4c
Subscribe for More Information
November 11, 2014
08:41 EDTENZYEnzymotec initiates clinical study of Vayarin
Enzymotec announced the initiation of a clinical study to evaluate the efficacy of Vayarin in adults with Attention Deficit Hyperactivity Disorder, or ADHD. The randomized, double-blind, placebo-controlled study will enroll 171 patients between the ages of eighteen and fifty-five. This will be a multi-center study in the United States, including the NYU School of Medicine. The study was designed to assess the efficacy of Vayarin in adults with ADHD, measured primarily by the ADHD Investigator Symptom Rating Scale.
08:11 EDTACSTAcasti Pharma receives NASDAQ notification regarding minimum bid requirements
Acasti Pharma announces that on November 7 it received notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum bid price of $1.00 per share for the last 30 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2) bid price. The NASDAQ notification has no immediate effect on the listing of the Corporation's shares. Under NASDAQ rule 5810(c)(3)(A) compliance period, the corporation has 180 calendar days, or until May 6, 2015, to regain compliance. If at any time over this period the bid price of Acasti's shares closes at $1.00 per share or more for a minimum of ten consecutive business days, NASDAQ will provide written confirmation of compliance and the matter will be closed. If Acasti does not regain compliance within the initial 180-day period, but meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for the NASDAQ Capital Market, except for the bid price requirement, the corporation may be eligible for an additional 180 calendar days to regain compliance. If the corporation is not granted additional time, then the securities will be subject to delisting, at which time the corporation may appeal the delisting determination to a NASDAQ Hearings Panel. The company intends to evaluate all available options to resolve the deficiency and regain compliance with the Minimum Bid Price Rule.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use